Search clinical trials for: Non Hodgkin's Follicular Lymphoma

Total 57230 results

Sana Biotechnology

Recruiting

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) (VIVID)

Non Hodgkin's Lymphoma | Large B-cell Lymphoma

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
AbbVie
Genmab

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico
Cho Pharma Inc.

Recruiting

A Study to Assess Safety and Efficacy of CHO-H01 in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

Taiwan, United States
Ruijin Hospital

Not yet recruiting

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Richter Syndrome | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sana Biotechnology

Recruiting

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Australia
BeiGene

Recruiting

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Refractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditions

China, Australia
Reid Merryman, MD
AbbVie; Genmab

Recruiting

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Follicular Lymphoma | Low Grade Non-Hodgkin's Lymphoma, Adult

United States
AbbVie

Recruiting

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Hematologic Cancer

United States, Israel, Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
University of Nebraska
Bristol-Myers Squibb

Recruiting

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Carna Biosciences, Inc.

Recruiting

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | B-cell Malignancy

United States
He Huang

Recruiting

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

China
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL)

Austria, Greece, Israel, Korea, Republic of, Spain, Hungary, Sweden, Switzerland, France, Poland, Taiwan, Australia, Denmark, New Zealand, Turkey, Italy, Netherlands, Belgium, Canada, South Africa, Czechia, Brazil, Germany, Argentina, United... and more
Iksuda Therapeutics Ltd.

Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin Lymphoma

Australia, Canada, United States
Mustang Bio
National Cancer Institute (NCI)

Recruiting

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | Waldenstrom's Macroglobulinemia Refractory | Chronic Lymphoid Leukemia in Relapse

United States
Century Therapeutics, Inc.

Recruiting

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1)

Aggressive Non-Hodgkin Lymphoma | R/R CD19-Positive B-Cell Malignancies | Indolent Non-Hodgkin Lymphoma

United States
2seventy bio

Recruiting

A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Diffuse Large B Cell Lymphoma (DLBCL)

United States
Chinese PLA General Hospital

Recruiting

IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Inert Non Hodgkin's Lymphoma

China
oubai, MD/PhD

Recruiting

R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden

Diffuse Large B Cell Lymphoma | Follicular Lymphoma Grade 3B

China
M.D. Anderson Cancer Center

Recruiting

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Richter Syndrome | Refractory Mantle Cell Lymphoma | Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory... and other conditions

United States
Emory University
National Cancer Institute (NCI); AstraZeneca

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Lymphoproliferative Disorder | Indolent Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
M.D. Anderson Cancer Center

Recruiting

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Recurrent High Grade B-Cell... and other conditions

United States
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
C. Babis Andreadis
University of California, Davis

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

United States
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States
Zhejiang DTRM Biopharma

Recruiting

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Follicular Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter's Transformation | Relapsed Chronic Lymphocytic Leukemia

United States
University of Washington
AstraZeneca

Recruiting

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

B-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Follicular Lymphoma | Splenic Marginal Zone Lymphoma | Mantle Cell Lymphoma | Indolent Non-hodgkin Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Nodal Marginal Zone Lymphoma

United States
Medical College of Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Central Nervous System Lymphoma | Mantle Cell Lymphoma (MCL) | Non Hodgkin Lymphoma (NHL)

United States
Beijing Mabworks Biotech Co., Ltd.

Recruiting

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Follicular Lymphoma and Marginal Zone Lymphoma

China
Malaghan Institute of Medical Research
Wellington Zhaotai Therapies Limited (WZTL)

Recruiting

ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy) (ENABLE)

Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Lymphomas Non-Hodgkin's B-Cell | Transformed Follicular Lymphoma (TFL) | Primary Mediastinal B-cell Lymphoma (PMBCL)

New Zealand
Hospices Civils de Lyon
The Lymphoma Academic Research Organisation

Recruiting

REal World Data in LYmphoma and Survival in Adults (REALYSA)

Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Diffuse Large B Lymphoma (DLBCL) | Marginal Zone Lymphoma (MZL) | T-cell Lymphoma (T-NHL) | Hodgkin's Lymphoma (HL) | Burkitt Lymphoma (BL))

France
Medical College of Wisconsin

Recruiting

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Follicular Lymphoma | Multiple Myeloma | Burkitt Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Lymphoma, Small Lymphocytic | Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Lymphomas Non-Hodgkin's B-Cell

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Lymphoma | Follicular Lymphoma | Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Juvenile Myelomonocytic Leukemia | Burkitt Lymphoma | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Leukemia | Mantle-Cell Lymphoma | Chronic Myelogenous... and other conditions

United States
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Genentech, Inc.; Pharmacyclics LLC.

Recruiting

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma | Indolent Non-hodgkin Lymphoma | Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage II Nodal Marginal Zone Lymphoma | Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma | Ann Arbor... and other conditions

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Auto Stem Cell Transplant for Lymphoma Patients

Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Recruiting

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Follicular Lymphoma | Multiple Myeloma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Non-Hodgkin Lymphoma | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Myelogenous Leukemia | Prolymphocytic Leukemia | Myelodysplasia | Acute Myeloid Leukemia... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Follicular Lymphoma | Non-Hodgkin's Lymphoma | NHL

United States
University College, London
Roche Pharma AG; Cancer Research UK

Completed

Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Lymphoma

New Zealand, United Kingdom, Australia
BeiGene

Active, not recruiting

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma (ROSEWOOD)

Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

Korea, Republic of, New Zealand, United States, China, Taiwan, Spain, Italy, Australia, Canada, United Kingdom, Belarus, Bulgaria, Czechia, France, Germany, Poland, Russian Federation
Epizyme, Inc.

Enrolling by invitation

A Study to Assess the Long-term Safety of Tazemetostat (TRuST)

Advanced Solid Tumors | Mesothelioma | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | Epitheliod Sarcoma (ES)

United States, France, United Kingdom, Poland, Australia, Belgium, Ukraine
Novartis Pharmaceuticals

Active, not recruiting

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Non-Hodgkin Lymphoma

Spain, Taiwan, Australia, Belgium, Germany, Italy, Singapore, Austria, France, Switzerland, Hong Kong, United States, Netherlands, Norway, United Kingdom, Brazil, China, Japan
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Anaplastic Large Cell Lymphoma | Recurrent Angioimmunoblastic T-Cell Lymphoma | Recurrent Mycosis Fungoides | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Refractory Anaplastic Large Cell Lymphoma | Subcutaneous... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Richter Syndrome | Refractory Transformed Non-Hodgkin Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Hoffmann-La Roche

Completed

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Follicular Lymphoma

United Kingdom, Belgium, United States, Australia, Canada, Germany
National Cancer Institute (NCI)

Active, not recruiting

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous... and other conditions

United States, Canada

Search clinical trials for: Non Hodgkin's Follicular Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations